WO1996008263A1 - Intracellular delivery of chemical agents to a specific cell type - Google Patents

Intracellular delivery of chemical agents to a specific cell type Download PDF

Info

Publication number
WO1996008263A1
WO1996008263A1 PCT/US1995/011515 US9511515W WO9608263A1 WO 1996008263 A1 WO1996008263 A1 WO 1996008263A1 US 9511515 W US9511515 W US 9511515W WO 9608263 A1 WO9608263 A1 WO 9608263A1
Authority
WO
WIPO (PCT)
Prior art keywords
chemical agent
seq
receptor
composition
ligand
Prior art date
Application number
PCT/US1995/011515
Other languages
English (en)
French (fr)
Inventor
Ramesh K. Prakash
Original Assignee
Theratech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech, Inc. filed Critical Theratech, Inc.
Priority to EP95932472A priority Critical patent/EP0781139A1/en
Priority to AU35507/95A priority patent/AU697469B2/en
Priority to JP8510273A priority patent/JPH10505835A/ja
Priority to BR9508951A priority patent/BR9508951A/pt
Priority to CZ97747A priority patent/CZ74797A3/cs
Priority to MX9701860A priority patent/MX9701860A/es
Priority to KR1019970701469A priority patent/KR970705404A/ko
Publication of WO1996008263A1 publication Critical patent/WO1996008263A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
PCT/US1995/011515 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type WO1996008263A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP95932472A EP0781139A1 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type
AU35507/95A AU697469B2 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type
JP8510273A JPH10505835A (ja) 1994-09-13 1995-09-12 特定の細胞型への化学試薬の細胞内送達
BR9508951A BR9508951A (pt) 1994-09-13 1995-09-12 Liberação intracelular de agentes químicos para um tipo específico de célula
CZ97747A CZ74797A3 (en) 1994-09-13 1995-09-12 Composition for specific intracellular introduction of a chemical agent and method of such introduction
MX9701860A MX9701860A (es) 1994-09-13 1995-09-12 Suministro intracelular de agentes quimicos, a un tipo especifico de celula.
KR1019970701469A KR970705404A (ko) 1994-09-13 1995-09-12 특정 세포형에 화학 물질의 세포내 수송(intracellular delivery of chemical agents to a specific cell type)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
US08/305,770 1994-09-13

Publications (1)

Publication Number Publication Date
WO1996008263A1 true WO1996008263A1 (en) 1996-03-21

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011515 WO1996008263A1 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type

Country Status (13)

Country Link
EP (1) EP0781139A1 (es)
JP (1) JPH10505835A (es)
KR (1) KR970705404A (es)
CN (1) CN1157570A (es)
AU (1) AU697469B2 (es)
BR (1) BR9508951A (es)
CA (1) CA2198361A1 (es)
CZ (1) CZ74797A3 (es)
HU (1) HUT77263A (es)
MX (1) MX9701860A (es)
PL (1) PL319100A1 (es)
WO (1) WO1996008263A1 (es)
ZA (1) ZA957688B (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011705A2 (en) * 1997-08-05 2000-06-28 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
EP2110142A3 (en) * 1999-09-23 2013-02-27 Syntaxin Limited Inhibition of secretion from non-neuronal cells
US8846602B2 (en) 1999-06-09 2014-09-30 Ktb Tumorforschungs Gmbh Process for producing an injectable medicament preparation
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191094C (zh) * 1997-11-19 2005-03-02 乔治敦大学 定向脂质体基因送递

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 56, issued 10 February 1989, NEMEROW et al., "Identification of an Epitope in the Major Envelope Protein of Epstein-Barr Virus that Mediates Viral Binding to the B Lymphocyte EBV Receptor (CR2)", pages 369-377. *
METHODS IN ENZYMOLOGY, Vol. 112, issued 1985, MOLTENI, "Dextran and Insulin Conjugates as Drug Carriers", pages 285-298. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011705A2 (en) * 1997-08-05 2000-06-28 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
EP1011705A4 (en) * 1997-08-05 2000-09-20 Watson Pharmaceuticals Inc CONJUGATES TARGETED AT THE INTERLEUKIN-2 RECEPTOR
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6693083B2 (en) 1997-08-05 2004-02-17 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
US8846602B2 (en) 1999-06-09 2014-09-30 Ktb Tumorforschungs Gmbh Process for producing an injectable medicament preparation
EP2110142A3 (en) * 1999-09-23 2013-02-27 Syntaxin Limited Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Also Published As

Publication number Publication date
AU697469B2 (en) 1998-10-08
CN1157570A (zh) 1997-08-20
PL319100A1 (en) 1997-07-21
HUT77263A (hu) 1998-03-02
ZA957688B (en) 1996-05-13
AU3550795A (en) 1996-03-29
CZ74797A3 (en) 1997-08-13
MX9701860A (es) 1997-06-28
CA2198361A1 (en) 1996-03-21
JPH10505835A (ja) 1998-06-09
KR970705404A (ko) 1997-10-09
BR9508951A (pt) 1999-04-06
EP0781139A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
US5428143A (en) Cytotoxic agent against specific virus infection
US6251866B1 (en) Conjugates targeted to the interleukin-2 receptor
JP2008521759A (ja) ＢＨ３−ｏｎｌｙタンパク質のＢＨ３ドメイン配列を含む融合タンパク質
AU1193999A (en) J-chain and analogues as epithelial cell targeting conjugates
JP2635035B2 (ja) Ｃｙｓコドン修飾ＤＮＡ
CA2406352A1 (en) Peptide conjugates for drug delivery
CA2035868A1 (en) Hybrid molecules
AU697469B2 (en) Intracellular delivery of chemical agents to a specific cell type
CA2276046A1 (en) Novel epithelial tissue targeting agent
JP2510846B2 (ja) ＰＥ４０Ａｂを含有するタンパク質抗ガン剤
MXPA97001860A (es) Suministro intracelular de agentes quimicos, a untipo especifico de celula
AU708304B2 (en) Targeting macromolecular prodrugs to T lymphocytes
CA2165413A1 (en) Methods for peptide synthesis and purification
US5621078A (en) Modified pseudomonas exotoxin PE40
JPH06503553A (ja) 改良されたドメイン間幾何を有するキメラ毒素類
WO1998051336A1 (en) Targeted delivery to t lymphocytes
AU2004203690B2 (en) Agonist peptide dimers
CA2299368A1 (en) Conjugates targeted to the interleukin-2 receptor
AU653365C (en) Protein structure of the plant toxin gelonin
AU653365B2 (en) Protein structure of the plant toxin gelonin
Riemen et al. Modified pseudomonas exotoxin PE 40
EP0389043A1 (en) Production of modified PE40

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195037.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995932472

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2198361

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019970701469

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1997-747

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/001860

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1995932472

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-747

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970701469

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970701469

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995932472

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-747

Country of ref document: CZ